Supreme Court Rules on the ACA: Implications for Pharma
(June 28, 2012)
The US Supreme Court released its ruling on the review of the challenges to the ACA. As you know, the implications of the justices’ decision are complex, with millions of lives impacted by this significant ruling. The Access Group has developed a brief analysis of the Court’s ruling and outlined implications for pharmaceutical, biotech, and medical device manufacturers. To view our analysis, click here
Introducing the Access Group and Its New Business Entities
(March 18, 2011)
Supreme Court Review of the 2010 Health Care Reform Law—How Might the Court’s Decisions Impact Pharmaceutical Companies?
This piece provides insight into the key issues/questions from the Patient Protection and Affordable Care Act reviewed by the Supreme Court and the implications that the Court’s decision may have on our industry. These issues/questions include
• Is the fine imposed upon persons who do not satisfy the individual mandate—known as the shared responsibility payment—a penalty or a tax?
• Is it constitutional for Congress to require most US citizens to purchase health insurance?
• Can the individual mandate be severed from the rest of the law?
• Can the federal government require states to expand their Medicaid programs as a condition of receiving funding?
The Access Group Lifecycle Management Philosophy Featured in The Suit Magazine
Access Group CEO Dave Gagliano reviews the firm’s model for success and offers his insights on issues that are impacting the changing US healthcare system.
For press inquiries about the Access Group, please contact Kristen Supchak at email@example.com, (908) 508-6759